Amicus Therapeutics, Inc. (NASDAQ:FOLD) Rating Lowered to Buy at BidaskClub
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.
A number of other brokerages have also weighed in on FOLD. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Robert W. Baird raised their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, July 12th. Cowen and Company restated a “buy” rating and issued a $16.00 target price (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Finally, J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a research note on Monday, June 5th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus price target of $13.42.
Shares of Amicus Therapeutics (FOLD) traded up 1.07% during trading on Wednesday, reaching $13.23. 1,524,241 shares of the company were exchanged. The stock’s market capitalization is $1.89 billion. The stock has a 50-day moving average of $11.40 and a 200 day moving average of $8.12. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $14.05.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.02. The firm had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.16 million. Amicus Therapeutics’s revenue for the quarter was up 50.0% compared to the same quarter last year. On average, equities analysts anticipate that Amicus Therapeutics will post ($1.44) earnings per share for the current fiscal year.
In other news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total value of $239,312.00. Following the completion of the sale, the insider now owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas raised its position in Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares during the last quarter. Princeton Alpha Management LP bought a new position in Amicus Therapeutics during the first quarter valued at about $106,000. DORCHESTER WEALTH MANAGEMENT Co bought a new position in Amicus Therapeutics during the second quarter valued at about $111,000. Creative Planning raised its position in Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares during the last quarter. Finally, Rockefeller Financial Services Inc. bought a new position in Amicus Therapeutics during the first quarter valued at about $136,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.